Mode
Text Size
Log in / Sign up
Phase 2 N=116 Randomized Triple-blind Treatment

Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672)

HIV Infections

Enrolled (actual)
116
Serious AEs
13.6%
Results posted
Jun 2021
Primary outcome: Primary: Change From Baseline in Log10 Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Week 48 of the Double-blind Period — 4.52; 4.50; 4.62; -1.78 Log10 copies/mL — p=0.0017

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Vicriviroc 30 mg (Drug); Vicriviroc 20 mg (Drug); Placebo (Drug); Background ART Regimen (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Merck Sharp & Dohme LLC
Primary completion
Oct 2007

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Log10 Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) at Week 48 of the Double-blind Period
4.52; 4.50; 4.62; -1.78; -1.73; -0.80 0.0017 sig
SECONDARY
Participants With ≥1.0 log10 Change From Baseline HIV RNA at Week 48 of the Double-blind Period
26; 25; 12 0.0052 sig
SECONDARY
Participants With HIV RNA <400 Copies/mL at Week 48 of the Double-blind Period
25; 24; 9 0.0007 sig
SECONDARY
Participants With a Time to Loss of Virologic Response (TLOVR) Based on 0.5 Log10 Reduction by 48 Weeks of the Double-blind Period
31; 32; 15; 1; 1; 1
SECONDARY
Change From Baseline in Log10 HIV RNA at Week 12 of the Double-blind Period
4.52; 4.50; 4.62; -2.11; -1.94; -1.11 0.0002 sig
SECONDARY
Change From Baseline in Log10 HIV RNA at Week 24 of the Double-blind Period
4.52; 4.50; 4.62; -2.07; -2.04; -0.96 0.0003 sig
SECONDARY
Change From Baseline CD4 Cells Count at Week 12 of the Double-blind Period
202.23; 202.10; 214.41; 109.85; 94.46; 52.09 0.0264 sig
SECONDARY
Change From Baseline CD4 Count at Week 24 of the Double-blind Period
202.23; 202.10; 214.41; 97.58; 103.58; 59.46 0.1525
SECONDARY
Change From Baseline CD4 Count at Week 48 of the Double-blind Period
202.23; 202.10; 214.41; 102.12; 133.88; 64.80 0.2603
SECONDARY
Change From Baseline CD4 Count at Month 42 of the Open Label Extension
366.16; -78.67
SECONDARY
Participants With <400 Copies/mL HIV RNA at Week 12 of the Double-blind Period
28; 25; 14 0.0031 sig
SECONDARY
Participants With <400 Copies/mL HIV RNA at Week 24 of the Double-blind Period
28; 29; 12 0.0009 sig
SECONDARY
Number of Participants With <50, 50 to <400, and ≥400 Copies/mL HIV RNA of the Open Label Extension
48; 42; 5; 1; 10; 5
SECONDARY
Participants With <50 Copies/mL HIV RNA at Week 12 of the Double-blind Period
18; 17; 8 0.0225 sig
SECONDARY
Participants With <50 Copies/mL HIV RNA at Week 24 of the Double-blind Period
25; 23; 9 0.0009 sig
SECONDARY
Participants With <50 Copies/mL HIV RNA at Week 48 of the Double-blind Period
22; 21; 5 0.0002 sig
SECONDARY
Participants With Acquired Immunodeficiency Syndrome (AIDS)-Defining Events of the Double-blind Period
0; 0; 1
SECONDARY
Participants With AIDS-defining Events of the Open Label Extension
1
SECONDARY
Time to Occurrence of an AIDS-defining Event of the Double-blind Period
256
SECONDARY
Observed Minimum Serum Concentration of Vicriviroc (Cmin) of the Double-blind Period
206.56; 156.95
SECONDARY
Observed Maximum (Peak) Plasma Concentration of Vicriviroc (Cmax) of the Double-blind Period
316.21; 229.33
SECONDARY
Area Under the Plasma Concentration Versus Time Curve of Vicriviroc (AUC) of the Double-blind Period
5795.62; 4314.88
SECONDARY
Participants With Detectable Vicriviroc Resistance of the Double-blind Period
1; 4; 0
SECONDARY
Participants With Detectable C-X-C Chemokine Receptor Type 4 (CXCR4)-Tropic Virus of the Double-blind Period
9; 7; 3; 8; 7; 2
SECONDARY
Participants With Detectable CXCR4-Tropic Virus and Immune Decline (≥50% Fall in CD4 Count From Baseline) of the Double-blind Period
3; 1; 2; 3; 1; 0

Summary

Vicriviroc (vye-kri-VYE-rock) is an investigational drug that belongs to a new class of drugs, called C-C chemokine receptor type 5 (CCR5) receptor blockers. This group of drugs blocks one of the ways human immunodeficiency virus (HIV) enters T-cells (the cells that fight infection). The purpose of this 48-week study is to evaluate 2 dose levels of vicriviroc in participants with HIV who have not responded adequately to standard HIV treatments. This study was designed to evaluate the safety and efficacy of doses of vicriviroc, when taken in combination with other HIV drugs, in terms of ability to decrease the level of HIV (viral load) in the blood. The primary objective of the study was to evaluate antiviral efficacy of two doses of Vicriviroc maleate compared to placebo in combination with a protease inhibitor (PI)-containing optimized antiretroviral therapy (ART) regimen in CCR5-tropic HIV infected individuals failing a standard ART regimen.

Eligibility Criteria

Inclusion Criteria

  • Adult participants with documented HIV infection with no detectable C-X-C Motif Chemokine Receptor 4 (CXCR4)
  • Prior therapy for ≥3 months with ≥3 classes of currently marketed (US FDA-approved) antiretroviral agents (nucleoside reverse transcriptase inhibitor, NRTIs, non-nucleoside reverse transcriptase inhibitor (NNRTIs), protease inhibitor (PIs), or fusion inhibitors) at any time prior to screening
  • HIV ribonucleic acid (RNA) ≥1000 copies/mL on a stable ART regimen for ≥6 weeks prior to Screening and ≥8 weeks prior to randomization
  • ≥1 genotypically documented resistance mutation to a reverse transcriptase (RT) inhibitor and ≥1 primary resistance mutation to a PI
  • Acceptable hematologic, renal and hepatic laboratory parameters

Exclusion Criteria

  • No history of previous malignancy (with the exceptions of cutaneous Kaposi's Sarcoma without visceral or mucosal involvement that resolved with highly active antiretroviral therapy (HAART) but without systemic anti-cancer treatment, and basal-cell carcinoma of skin surgically resected with disease-free margins on pathology exam)
  • Treatment with cytotoxic cancer chemotherapy,
  • Recurrent seizure, or central nervous system (CNS) condition or drug use predisposing to seizure in the opinion of the investigator
  • No active acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00243230). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search